Lexus India launches Lexus Life, an exclusive ownership experience program for guests #LexusLife aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.
Retailer
Planet 13 Holdings Inc. (CSE:PLTH) (OTCQB:PLNHF) reported single-day record sales of $543,000 on April 20. Meanwhile,
Eaze, California s largest marketplace for legal cannabis delivery, announced a 185% surge in deliveries (compared to any other Tuesday in 2021), with an average basket of $200, up 50% from the same day in 2020.
“Cannabis consumers moved to delivery as their preferred way of shopping last year, so we re not surprised to see such a strong 420 in 2021,” said Ro Choy, CEO of Eaze. “Even as daily life begins to return to normal, consumers are staying with the convenience of delivery. It s the future of this industry.”
Debra Borchardt, CEO of Green Market Report, added, “The April 20 holiday is becoming the largest sales day of the year for the industry. Headset reported logging $60,000 in sales per minute, while Planet 13 said it did over half a million sales on Tuesday. Even Ayr Wellness clocked in an amazing $1.2 million day across its stores.
Aion Therapeuticâs Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells April 21 | 2021
 Aion Therapeutic Inc. (CSE: AION) (â Aion Therapeutic â or the â Company â) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the â Aion Mushroom Preparations â or â Preparations â) showed high efficacy in killing HER2+ breast cancer cells, ER+PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity. As shown in recently completed third-party independent and carefully controlled 3D-spheroid cell culture studies performed at BIOENSIS laboratories, these cytotoxicity studies demonstrated direct killing of the breast cancer cells by the Aion Mushroom Preparations, which suggests such preparations may be effective in treating HER2+ breast cancer, ER+/PR+ breast cancer, and the very difficult to treat tripl